X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.02 (-0.67%)
Close on Nov 19, 2026Market cap $293.47MP/E –Yield –
X4 Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
X4 Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2025 was -$85.62M. For fiscal 2025 it was -$85.62M. The highest annual figure on record is -$21.69M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.62M | – |
| FY2024 | Dec 31, 2024 | -$131.23M | – |
| FY2023 | Dec 31, 2023 | -$96.57M | – |
| FY2022 | Dec 31, 2022 | -$77.21M | – |
| FY2021 | Dec 31, 2021 | -$71.52M | – |
| FY2020 | Dec 31, 2020 | -$60.18M | – |
| FY2019 | Dec 31, 2019 | -$48.23M | – |
| FY2018 | Dec 31, 2018 | -$25.42M | – |
| FY2017 | Dec 31, 2017 | -$21.69M | – |
| FY2016 | Dec 31, 2016 | -$21.71M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$15.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$64.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.91M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.32M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.51M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.81M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.47M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.08M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.32M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.30M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.75M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.73M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.69M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.67M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.11M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.39M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.53M | – |
See a number that looks wrong?